These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21751539)

  • 21. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
    Zanchetti A
    Blood Press Suppl; 1995; 3():38-46. PubMed ID: 8535541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
    Kaaja R; Manhem K; Tuomilehto J
    Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of moxonidine in the treatment of hypertension.
    Schachter M; Luszick J; Jäger B; Verboom C; Söhlke E
    Drug Saf; 1998 Sep; 19(3):191-203. PubMed ID: 9747666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moxonidine suitable for hypertensive menopausal women with metabolic syndrome.
    Cardiovasc J S Afr; 2005; 16(3):186. PubMed ID: 16049602
    [No Abstract]   [Full Text] [Related]  

  • 25. Moxonidine for hypertension.
    Drug Ther Bull; 1997 May; 35(5):33-6. PubMed ID: 9282418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The efficacy of antihypertension drugs and their combinations in the non-treated hypertension].
    Ruksin VV; Grishin OV; Chiritso MM
    Med Tr Prom Ekol; 2013; (5):7-11. PubMed ID: 24000722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of metabolic risk factors with uncontrolled hypertension: comparison of the several definitions of metabolic syndrome.
    Cortez-Dias N; Martins SR; Belo A; Fiuza M;
    J Hypertens; 2013 Oct; 31(10):1991-7. PubMed ID: 23811998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension].
    Kobalava ZhD; Tolkacheva VV; Ignat'ev IV; Glezer MG; Kuzin AI; Karpov IuA; Konradi AO; Zheleznykh EA
    Ter Arkh; 2005; 77(1):46-51. PubMed ID: 15759454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pecularities of prolonged use of moxonidine in patients with hypertension associated with metabolic syndrome.
    Kseneva SI; Borodulina EV; Semiglazova TA; Kulakova NV; Tarasova IV; Trifonova OJ; Gridneva TD; Udut VV
    Bull Exp Biol Med; 2011 Aug; 151(4):400-4. PubMed ID: 22448351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological properties of the central antihypertensive agent, moxonidine.
    Edwards LP; Brown-Bryan TA; McLean L; Ernsberger P
    Cardiovasc Ther; 2012 Aug; 30(4):199-208. PubMed ID: 21884003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The use of moxonidine in patients with essential hypertension combined with metabolic syndrome].
    Syrtlanova ER; Gil'mutdinova LT
    Kardiologiia; 2003; 43(3):33-5. PubMed ID: 12913980
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.
    Ebinç H; Ozkurt ZN; Ebinç FA; Ucardag D; Caglayan O; Yilmaz M
    J Int Med Res; 2008; 36(1):80-7. PubMed ID: 18230271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moxonidine: a review of safety and tolerability after seven years of clinical experience.
    Schachter M
    J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome.
    Laurent S; Boutouyrie P;
    Hypertension; 2014 Oct; 64(4):709-16. PubMed ID: 25001274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive efficacy of moxonidine in primary care: a 'real-life' study.
    Schachter M; Mitchell G; Niziol C; Abhyankar BA
    Int J Clin Pract; 2003; 57(6):479-82. PubMed ID: 12918886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Haenni A; Lithell H
    J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
    Widimský J; Sirotiaková J
    Curr Med Res Opin; 2006 Jul; 22(7):1287-94. PubMed ID: 16834827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.